-
Options Brief: Affymax
Tuesday, August 9, 2011 - 1:46pm | 68Shares of Affymax (NASDAQ: AFFY) are lower on the session by 7.49%, trading at $4.32. Overall put volume is now running at 5.37x the daily average, with 97% of all puts traded being purchases on the offer. 2,073 contracts have traded on the session so far. Affymax, Inc. is a biopharmaceutical...
-
McNicoll, Lewis & Vlak Reiterates Inhibitex Buy, $7 PT
Tuesday, August 9, 2011 - 1:39pm | 89McNicoll, Lewis & Vlak reiterated its Inhibitex (NASDAQ: INHX) Buy rating and $7 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "We reiterate our BUY rating and $7 price target. INHX plans to actively engage the FDA in designing a Phase IIb...
-
Market Losers
Tuesday, August 9, 2011 - 1:33pm | 182Sykes Enterprises (NASDAQ: SYKE) is trading down over 26% near $11.70 after reporting Q2 earnings. AOL (NYSE: AOL) is trading down over 24.60% near $11.35 after reporting Q2 earnings. Idenix Pharma (NASDAQ: IDIX) is trading down over 18% near $4.27 after reporting Q2 earnings. DTS (NASDAQ: DTSI) is...
-
Major Pops In Large And Small Cap Stocks
Tuesday, August 9, 2011 - 1:08pm | 184The markets are sharply higher as they get an oversold bounce ahead of the FOMC Policy Statement. In the last two weeks, the markets have dumped over 15%. Everything from major market leaders like Caterpillar Inc. (NYSE: CAT) and Apple Inc. (NASDAQ: AAPL) to small cap runners like OXiGENE, Inc. (...
-
Options Brief: Alexion Pharmaceuticals
Tuesday, August 9, 2011 - 12:59pm | 94Shares of Alexion Pharmaceuticals (NASDAQ: ALXN) are higher on the session by 4.29%, trading at $50.11. Overall call volume is now running at 4.99x the daily average, with 86% of all calls traded being purchases on the offer. 3,010 contracts have traded on the session so far. Alexion...
-
Monday's NASDAQ Top Percentage Gainers: BroadSoft, Globalstar, ZIOPHARM, Novatel Wireless
Tuesday, August 9, 2011 - 11:44am | 496POINT ROBERTS - August 9, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Aug. 08, 2011. In Monday's session, BroadSoft Inc was leading the top gainer as the stock soared 9.70%. As the Dow , NASDAQ and...
-
Bank of America Initiates Inhibitex At Buy, $6 PO
Tuesday, August 9, 2011 - 9:29am | 25Bank of America has initiated coverage on Inhibitex (NASDAQ: INHX) with a Buy rating and $6 price objective.
-
UPDATE: Rodman & Renshaw Reiterates Market Outperform on AVI BioPharma, Reduces PT to $2
Tuesday, August 9, 2011 - 9:24am | 44Rodman & Renshaw reiterated its Market Outperform rating on AVI BioPharma (NASDAQ: AVII). At the same time, the rating agency reduced its price target on the company's stock from $4 to $2. On Monday, AVII closed the day at $1.15.
-
Desjardins Upgrades AEZS To Buy
Tuesday, August 9, 2011 - 9:18am | 20Desjardins Securities has upgraded Aeterna Zentaris (NASDAQ: AEZS) from Hold to Buy.
-
Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis
Tuesday, August 9, 2011 - 8:01am | 169Biogen Idec (NASDAQ: BIIB) and Abbott (NYSE: ABT) today announced positive top-line results from SELECT, a global, registrational Phase 2b clinical trial designed to evaluate the investigational compound daclizumab high-yield process in people with relapsing-remitting multiple sclerosis over one...
-
A Peek Into The Market Before The Trading Starts
Tuesday, August 9, 2011 - 7:33am | 385Pre-open movers US stock futures are higher this morning, as investors are awaiting the Federal Reserve's statement on monetary policy. Futures for the Dow Jones Industrial Average surged 95 points to 10,821.00 and S&P 500 index futures rose 13.00 points to 1,124.30. Nasdaq 100 futures gained...
-
Lexicon Pharmaceuticals Announces Phase 2 Trial of LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
Tuesday, August 9, 2011 - 7:09am | 90Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced positive, top-line proof-of-concept data from its recently completed Phase 2 study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from...
-
Cepheid Announces Release of Updated Xpert BCR-ABL Monitor Test
Tuesday, August 9, 2011 - 7:06am | 78Cepheid (NASDAQ: CPHD) today announced the release of an updated Xpert® BCR-ABL Monitor test, now reporting results to the International Scale. The test is being released as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. The test, which runs on...
-
Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
Tuesday, August 9, 2011 - 7:03am | 122Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today results from a Pathology Working Group's re-adjudication of female rat mammary tumor diagnoses from a two-year rat carcinogenicity study of lorcaserin. Arena convened the PWG in response to the lorcaserin Complete Response...
-
Rodman & Renshaw Reiterates Market Outperform and $16 on Adventrx Pharmaceuticals
Tuesday, August 9, 2011 - 6:56am | 61Rodman & Renshaw reiterated its Market Outperform rating on Adventrx Pharmaceuticals (NYSE: ANX). At the same time, the rating agency left its price target on the company's unchanged at $16. On Monday, ANX lost 15.04% of their value to finish the day at $2.09. Its shares started to rebound in...